Efficacy of Drug X in Metastatic Lung Cancer: A Phase 3 Study
Key Findings
Study demonstrated a 45% improvement in progression-free survival (PFS) compared to standard therapy. Patients receiving Drug X showed significantly better quality of life scores with manageable safety profile. Response rate was 38% versus 22% in control group.
Summary
Phase 3 study demonstrates significant improvement in progression-free survival with Drug X in metastatic NSCLC patients.
Study Design
Phase 3, randomized, double-blind, placebo-controlled trial enrolling 500 patients with previously treated metastatic non-small cell lung cancer. Patients had received at least one prior platinum-based chemotherapy regimen.
Methods
Patients were randomized 1:1 to receive Drug X 200mg daily or placebo. Stratification factors included ECOG performance status, number of prior therapies, and smoking history. Primary endpoint was progression-free survival assessed by blinded independent central review per RECIST 1.1 criteria.
Results
Median PFS was 12.5 months in Drug X arm versus 8.2 months in placebo arm (HR=0.65, 95% CI: 0.52-0.81, p<0.001). Overall response rate was 38% versus 22%. Median overall survival was 24.3 months versus 18.1 months (HR=0.74, p=0.012). Grade 3+ adverse events occurred in 42% of Drug X patients versus 38% of placebo patients.
Conclusions
Drug X demonstrates significant clinical benefit in patients with metastatic lung cancer previously treated with chemotherapy, representing a new treatment option for this patient population. The safety profile was consistent with previous studies and manageable in the community setting.
Full Abstract
This randomized, double-blind, placebo-controlled Phase 3 trial evaluated Drug X in patients with previously treated metastatic non-small cell lung cancer (NSCLC). The study enrolled 500 patients across 75 centers in North America and Europe.